Your session is about to expire
← Back to Search
BMS-986340 + Nivolumab/Docetaxel for Advanced Solid Tumors
Study Summary
This trial is testing a new drug, BMS-986340, to see if it is safe and works well against advanced solid tumors when used alone or with another drug, nivolumab.
- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Pancreatic Adenocarcinoma
- Oral Squamous Cell Carcinoma
- Melanoma
- Bladder Cancer
- Breast Cancer
- Renal Cell Carcinoma
- Cervical Cancer
- Gastric Cancer
- Colorectal Cancer
- Ovarian Tumors
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have cancer that has spread to the tissues surrounding the brain and spinal cord.You have another cancer that needs treatment, or you had cancer in the past 2 years.You have had an organ or tissue transplant before.You have a heart condition that is not well controlled or is very serious.You have a history of lung disease or currently have lung problems.You need to provide a tumor sample before and during treatment for testing.You are able to carry out all regular activities without any restrictions (0) or you are restricted in physically strenuous activity but can perform light work or office work (1).You have advanced or spreading disease and have already tried or cannot use the standard treatments that work for your condition.You have a tumor that can be measured and a tumor that can be biopsied, but certain types of biopsies are not allowed.The latest treatment didn't stop the disease from getting worse, as shown in imaging tests.You have already received the usual treatments for your condition, except for a specific type of treatment called docetaxel for advanced cancer.You have a type of cancer that started in the brain or spinal cord.You have cancer that has spread to the brain and it has not been treated yet.You have an ongoing autoimmune disease or are suspected to have one.You have taken corticosteroids or other immune-suppressing medications recently.You have advanced or spreading disease and have already tried treatments that are known to work for your condition.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Part 1C: BMS-986340 + Docetaxel Dose Escalation
- Group 2: Part 2A: BMS-986340 Dose Expansion
- Group 3: Part 1B: BMS-986340 + Nivolumab Dose Escalation
- Group 4: Part 2B: BMS-986340 + Nivolumab Dose Expansion
- Group 5: Part 1A: BMS-986340 Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What therapeutic purpose does BMS-986340 usually fulfill?
"BMS-986340 is a common treatment for malignant neoplasms, such as unresectable melanoma and squamous cell carcinomae melanoma and squamous cell carcinoma. It can also be used to manage metastatic esophageal adenocarcinoma."
Are there any precedents of research into BMS-986340?
"Since its inception at Local Institution in 2012, BMS-986340 has been tested via 250 completed clinical trials. Presently there are 718 active studies being conducted around the world with a significant portion centered in Edmonton, Oregon."
What is the current population of participants in this experiment?
"This trial, sponsored by Bristol-Myers Squibb, requires 185 patients who meet its enrollment criteria. The experiment will be carried out at Local Institution in Edmonton, Oregon and Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer, Oregon and Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protocol in Portland, Quebec."
At what locations can patients access this clinical trial?
"This clinical trial is actively recruiting patients from 15 different centres. Examples of these include Local Institution in Edmonton, Columbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protocol in Portland, and Memorial Sloan Kettering Nassau in Montréal."
Has this trial of treatment ever been conducted before?
"BMS-986340 has been under research since 2012 when Ono Pharmaceutical Co. Ltd. initiated a clinical trial involving 659 participants. After passing Phase 1 & 2, 718 studies concerning the drug have become active across 49 nations and 2356 cities worldwide."
Are there any current opportunities to join this experiment?
"Affirmative. Data hosted on clinicaltrials.gov attests to this medical study's active recruitment, which commenced on May 27th 2021 and is still ongoing as of September 28th 2022. The trial requires 185 participants that will be recruited from 15 different sites."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger